The ‘Double Invisibility’ of Female Sexuality in Schizophrenia: A Call for Recognition

Sexual dysfunction is among the most prevalent yet least systematically assessed comorbidities in schizophrenia. A meta-analysis of 72 studies enrolling 21,076 participants across 33 countries reported a pooled prevalence of 60.0% (95% CI: 48.0–70.8) for sexual dysfunction specifically in women with schizophrenia, with orgasm dysfunction (28%) and amenorrhoea (25%) as the most frequent female-specific presentations. ¹ Despite this burden, sexual functioning is absent from standard psychiatric outcome instruments, excluded from most functional recovery frameworks, and rarely elicited in clinical consultations. ² The present letter argues that this neglect reflects two compounding and mutually reinforcing silences, what we term the ‘double invisibility’ of female sexuality in schizophrenia.

The first operates at the level of serious mental illness broadly. Sexual health in psychosis remains a clinical afterthought; patients are seldom asked, and spontaneous disclosure is rare, particularly in cultural settings where the topic carries stigma. ³ Montejo et al., in a global review of sexual health across severe mental disorders, documented that treatment-related sexual adverse effects persist over time yet are consistently under-recognised by clinicians and scarcely investigated in controlled trials. ³ The second silence is sex-specific. Research on sexual dysfunction in schizophrenia has been skewed towards male presentations, erectile dysfunction, ejaculatory disturbance, and hyperprolactinaemia-related sequelae, with women under-represented in both investigative and clinical frameworks. These two silences do not merely coexist; each amplifies the other, producing a gap that is systematic rather than incidental.

The dominant clinical explanatory model attributes FSD in schizophrenia largely to antipsychotic-induced hyperprolactinaemia, via suppression of gonadotrophin-releasing hormone, resulting in diminished libido, menstrual irregularity, and anorgasmia. ⁴ This framing, while pharmacologically valid, is reductive. Barker and Vigod, reviewing sexual health outcomes in women with schizophrenia specifically, documented that dysfunction manifests before antipsychotic exposure and is substantially shaped by illness-intrinsic variables: negative symptoms, affective blunting, body image disturbance, cognitive deficits that impair relational reciprocity, and the disproportionate prevalence of trauma in this population. ⁴ A causally narrow attribution to medication alone misdirects clinical assessment and limits therapeutic options.

Data from India illustrate the scope of the problem in this region. Simiyon et al. found that 70% of married women with schizophrenia at a tertiary centre met criteria for clinically significant FSD on the Female Sexual Function Index, with impaired desire present universally and marital quality the strongest independent correlate on multivariate analysis. ⁵ No validated, schizophrenia-specific instrument for FSD assessment is in routine clinical use. The PANSS, GAF, and comparable global rating scales capture nothing of sexual functioning. The Indian evidence base on this topic is thin relative to its clinical importance, and this journal, as the primary peer-reviewed forum for psychosexual research in South and South-East Asia, is well-placed to address that gap. ⁶

Evidence-based approaches are available. Validated instruments, such as the Female Sexual Function Index, can be incorporated into routine psychiatric review without undue burden. Antipsychotic selection in women of reproductive age should explicitly account for differential prolactin-raising liability. Research designs should include female-specific sexual outcomes as pre-specified endpoints rather than exploratory addenda. Postgraduate psychiatric training must treat FSD in psychosis as a core clinical competency rather than a subspeciality concern.

Sexual dysfunction in women with schizophrenia is prevalent, multidetermined, and clinically addressable. Its continued marginalisation reflects a failure of professional culture as much as a gap in evidence. The double invisibility described here is correctable, but only once it is named.